Published in Cancer Cell on March 01, 2005
Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients | NCT00856791
Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin | NCT00861328
Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer (2009) 9.26
Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov (2010) 3.84
Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression. Nat Cell Biol (2008) 2.68
Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol Cell Biol (2006) 2.63
Chemical genetics reveals the requirement for Polo-like kinase 1 activity in positioning RhoA and triggering cytokinesis in human cells. Proc Natl Acad Sci U S A (2007) 2.37
A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling. Cell (2016) 2.26
Different Plk1 functions show distinct dependencies on Polo-Box domain-mediated targeting. Mol Biol Cell (2005) 2.09
A cell-penetrating ARF peptide inhibitor of FoxM1 in mouse hepatocellular carcinoma treatment. J Clin Invest (2006) 2.02
Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. J Clin Oncol (2008) 1.84
Molecular and structural basis of polo-like kinase 1 substrate recognition: Implications in centrosomal localization. Proc Natl Acad Sci U S A (2007) 1.57
Serendipitous alkylation of a Plk1 ligand uncovers a new binding channel. Nat Chem Biol (2011) 1.49
A coupled chemical-genetic and bioinformatic approach to Polo-like kinase pathway exploration. Chem Biol (2007) 1.42
Polo-like kinase 1 is essential for early embryonic development and tumor suppression. Mol Cell Biol (2008) 1.29
Centrosome-associated regulators of the G(2)/M checkpoint as targets for cancer therapy. Mol Cancer (2009) 1.23
Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na. Leuk Res (2011) 1.20
Targeting Polo-Like Kinases: A Promising Therapeutic Approach for Cancer Treatment. Transl Oncol (2015) 1.12
Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ON 01910.Na, a mitotic progression modulator, in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 1.11
Polo-like kinase 1 (PLK1) regulates interferon (IFN) induction by MAVS. J Biol Chem (2009) 1.11
ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress. Clin Cancer Res (2012) 1.08
The balance of Polo-like kinase 1 in tumorigenesis. Cell Div (2009) 1.00
pH-responsive polymeric sirna carriers sensitize multidrug resistant ovarian cancer cells to doxorubicin via knockdown of polo-like kinase 1. Mol Pharm (2010) 1.00
Investigation of unanticipated alkylation at the N(π) position of a histidyl residue under Mitsunobu conditions and synthesis of orthogonally protected histidine analogues. J Org Chem (2011) 1.00
Novel drugs for older patients with acute myeloid leukemia. Leukemia (2014) 0.99
New combination therapies with cell-cycle agents. Curr Opin Investig Drugs (2008) 0.98
Signal transduction inhibitors in treatment of myelodysplastic syndromes. J Hematol Oncol (2013) 0.95
Expression analysis of mitotic spindle checkpoint genes in breast carcinoma: role of NDC80/HEC1 in early breast tumorigenicity, and a two-gene signature for aneuploidy. Mol Cancer (2011) 0.95
Polo-like kinase 1 as predictive marker and therapeutic target for radiotherapy in rectal cancer. Am J Pathol (2010) 0.95
Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes. Br J Haematol (2013) 0.94
Effects on polo-like kinase 1 polo-box domain binding affinities of peptides incurred by structural variation at the phosphoamino acid position. Bioorg Med Chem (2012) 0.94
Tumor inhibition by genomically integrated inducible RNAi-cassettes. Nucleic Acids Res (2006) 0.93
Mono-anionic phosphopeptides produced by unexpected histidine alkylation exhibit high plk1 polo-box domain-binding affinities and enhanced antiproliferative effects in hela cells. Biopolymers (2014) 0.93
Cell death signaling and anticancer therapy. Front Oncol (2011) 0.91
Plk1-targeted small molecule inhibitors: molecular basis for their potency and specificity. Mol Cells (2011) 0.90
Ataxia telangiectasia-mutated- and Rad3-related protein regulates the DNA damage-induced G2/M checkpoint through the Aurora A cofactor Bora protein. J Biol Chem (2013) 0.88
Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies. Clin Cancer Res (2014) 0.88
Rigosertib is a more effective radiosensitizer than cisplatin in concurrent chemoradiation treatment of cervical carcinoma, in vitro and in vivo. Int J Radiat Oncol Biol Phys (2014) 0.88
Recent Advances and New Strategies in Targeting Plk1 for Anticancer Therapy. Trends Pharmacol Sci (2015) 0.87
hPEBP4 as a predictive marker for the pathological response of rectal cancer to preoperative radiotherapy. Int J Colorectal Dis (2012) 0.87
Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay. Oncogene (2008) 0.87
Reduced efficacy of the Plk1 inhibitor BI 2536 on the progression of hepatocellular carcinoma due to low intratumoral drug levels. Neoplasia (2012) 0.86
Phase I study of ON 01910.Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignancies. Leukemia (2013) 0.86
Computational analysis of phosphopeptide binding to the polo-box domain of the mitotic kinase PLK1 using molecular dynamics simulation. PLoS Comput Biol (2010) 0.85
Allosteric IGF-1R Inhibitors. ACS Med Chem Lett (2010) 0.85
Differential determinants of cancer cell insensitivity to antimitotic drugs discriminated by a one-step cell imaging assay. J Biomol Screen (2013) 0.84
Molecular targeting of the oncoprotein PLK1 in pediatric acute myeloid leukemia: RO3280, a novel PLK1 inhibitor, induces apoptosis in leukemia cells. Int J Mol Sci (2015) 0.84
Involvement of polo-like kinase 1 (Plk1) in mitotic arrest by inhibition of mitogen-activated protein kinase-extracellular signal-regulated kinase-ribosomal S6 kinase 1 (MEK-ERK-RSK1) cascade. J Biol Chem (2012) 0.84
Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma. J Invest Dermatol (2015) 0.84
The natural product Aristolactam AIIIa as a new ligand targeting the polo-box domain of polo-like kinase 1 potently inhibits cancer cell proliferation. Acta Pharmacol Sin (2009) 0.84
Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer. Expert Opin Investig Drugs (2013) 0.83
Polo-like kinase 1, on the rise from cell cycle regulation to prostate cancer development. Protein Cell (2012) 0.83
Targeting polo-like kinase 1 in acute myeloid leukemia. Ther Adv Hematol (2015) 0.82
Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest. Cancer Sci (2015) 0.82
The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas. Mol Cancer Ther (2013) 0.81
Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer (2017) 0.81
Polo-like kinase 1 inhibition sensitizes neuroblastoma cells for vinca alkaloid-induced apoptosis. Oncotarget (2016) 0.80
Plk1 Inhibitors in Cancer Therapy: From Laboratory to Clinics. Mol Cancer Ther (2016) 0.80
Prevention of Doxorubicin cardiopathic changes by a benzyl styryl sulfone in mice. Genes Cancer (2011) 0.79
Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome. Sci Rep (2014) 0.79
Robust Classification of Small-Molecule Mechanism of Action Using a Minimalist High-Content Microscopy Screen and Multidimensional Phenotypic Trajectory Analysis. PLoS One (2016) 0.78
RNA interference against polo-like kinase-1 in advanced non-small cell lung cancers. J Clin Bioinforma (2011) 0.78
Pharicin A, a novel natural ent-kaurene diterpenoid, induces mitotic arrest and mitotic catastrophe of cancer cells by interfering with BubR1 function. Cell Cycle (2010) 0.78
PLK1, A Potential Target for Cancer Therapy. Transl Oncol (2016) 0.77
Yeast Polo-like kinase substrates are nailed with the right tools. Genome Biol (2008) 0.77
Retracted Peptide-based inhibitors of Plk1 polo-box domain containing mono-anionic phosphothreonine esters and their pivaloyloxymethyl prodrugs. Chem Biol (2013) 0.77
(Z)-1-aryl-3-arylamino-2-propen-1-ones, highly active stimulators of tubulin polymerization: synthesis, structure-activity relationship (SAR), tubulin polymerization, and cell growth inhibition studies. J Med Chem (2012) 0.77
Pharmacological inhibition of Polo-like kinase 1 (PLK1) by BI-2536 decreases the viability and survival of hamartin and tuberin deficient cells via induction of apoptosis and attenuation of autophagy. Cell Cycle (2015) 0.77
Computational design of targeted inhibitors of polo-like kinase 1 (plk1). Bioinform Biol Insights (2012) 0.77
PLK-1 Targeted Inhibitors and Their Potential against Tumorigenesis. Biomed Res Int (2015) 0.77
Efficacy of the polo-like kinase inhibitor rigosertib, alone or in combination with Abelson tyrosine kinase inhibitors, against break point cluster region-c-Abelson-positive leukemia cells. Oncotarget (2015) 0.76
Inhibition of Ras/Raf/MEK/ERK Pathway Signaling by a Stress-Induced Phospho-Regulatory Circuit. Mol Cell (2016) 0.76
Phase 1 study of intravenous rigosertib (ON 01910.Na), a novel benzyl styryl sulfone structure producing G2/M arrest and apoptosis, in adult patients with advanced cancer. Am J Cancer Res (2013) 0.76
ON 01910.Na (rigosertib) inhibits PI3K/Akt pathway and activates oxidative stress signals in head and neck cancer cell lines. Oncotarget (2016) 0.75
Identification of key genes induced by platelet-rich plasma in human dermal papilla cells using bioinformatics methods. Mol Med Rep (2016) 0.75
Inhibiting PLK1 induces autophagy of acute myeloid leukemia cells via mammalian target of rapamycin pathway dephosphorylation. Oncol Rep (2017) 0.75
Application of a liquid chromatography-tandem mass spectrometry (LC/MS/MS) method to the pharmacokinetics of ON01910 in brain tumor-bearing mice. J Pharm Biomed Anal (2011) 0.75
Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain. Oncotarget (2016) 0.75
Dysregulations in the PI3K pathway and targeted therapies for head and neck squamous cell carcinoma. Oncotarget (2017) 0.75
Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock? Target Oncol (2017) 0.75
Germ line transmission of the Cdk4(R24C) mutation facilitates tumorigenesis and escape from cellular senescence. Mol Cell Biol (2002) 1.58
JAKs, STATs and Src kinases in hematopoiesis. Oncogene (2002) 1.56
Activation of p38alpha/beta MAPK in myogenesis via binding of the scaffold protein JLP to the cell surface protein Cdo. J Cell Biol (2006) 1.52
Conditional c-myb knockout in adult hematopoietic stem cells leads to loss of self-renewal due to impaired proliferation and accelerated differentiation. Proc Natl Acad Sci U S A (2009) 1.48
Cyclin-dependent kinase 4 expression is essential for neu-induced breast tumorigenesis. Cancer Res (2005) 1.46
DH166, a beta-carboline derivative, inhibits the kinase activity of PLK1. Cancer Biol Ther (2009) 1.42
Increased angiogenesis in Cdk4(R24C/R24C):Apc(+/Min) intestinal tumors. Cell Cycle (2010) 1.40
Pseudotumors associated with total hip arthroplasty. J Bone Joint Surg Am (2012) 1.39
Transforming growth factor-beta suppresses nonmetastatic colon cancer through Smad4 and adaptor protein ELF at an early stage of tumorigenesis. Cancer Res (2005) 1.37
Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells. Oncogene (2009) 1.35
Jak/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies. Genes Cancer (2010) 1.34
Requirement of c-myb in T cell development and in mature T cell function. Proc Natl Acad Sci U S A (2004) 1.32
A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc Natl Acad Sci U S A (2005) 1.30
JLP: A scaffolding protein that tethers JNK/p38MAPK signaling modules and transcription factors. Proc Natl Acad Sci U S A (2002) 1.22
Constructing and deriving reciprocal trigonometric relations: a functional analytic approach. J Appl Behav Anal (2009) 1.21
Anti-inflammatory, analgesic and antipyretic properties of Clitoria ternatea root. Fitoterapia (2003) 1.14
Retracted The cellular source for APOBEC3G's incorporation into HIV-1. Retrovirology (2011) 1.08
Effect of ON 01910.Na, an anticancer mitotic inhibitor, on cell-cycle progression correlates with RanGAP1 hyperphosphorylation. Cancer Res (2011) 1.08
CDK4: A Key Player in the Cell Cycle, Development, and Cancer. Genes Cancer (2012) 1.07
Evaluation of antipyretic potential of Cleome viscosa Linn. (Capparidaceae) extract in rats. J Ethnopharmacol (2003) 1.06
Destabilization of Bcr-Abl/Jak2 Network by a Jak2/Abl Kinase Inhibitor ON044580 Overcomes Drug Resistance in Blast Crisis Chronic Myelogenous Leukemia (CML). Genes Cancer (2010) 1.05
JLP associates with kinesin light chain 1 through a novel leucine zipper-like domain. J Biol Chem (2005) 1.03
Molecular mechanisms associated with the regulation of apoptosis by the two alternatively spliced products of c-Myb. Mol Cell Biol (2003) 1.03
Function analysis of sequences in human APOBEC3G involved in Vif-mediated degradation. Virology (2007) 1.02
Preclinical pharmacokinetics and in vitro activity of ON 01910.Na, a novel anti-cancer agent. Cancer Chemother Pharmacol (2009) 1.00
Studies on analgesic activity of Cleome viscosa in mice. Fitoterapia (2003) 1.00
Design, synthesis, and biological evaluation of (E)-styrylbenzylsulfones as novel anticancer agents. J Med Chem (2007) 0.98
Design, synthesis and evaluation of (E)-alpha-benzylthio chalcones as novel inhibitors of BCR-ABL kinase. Bioorg Med Chem (2010) 0.97
An in vivo functional screen uncovers miR-150-mediated regulation of hematopoietic injury response. Cell Rep (2012) 0.97
Alkaloids from the root of Isatis indigotica. J Nat Prod (2012) 0.95
Transforming growth factor-β adaptor, β2-spectrin, modulates cyclin dependent kinase 4 to reduce development of hepatocellular cancer. Hepatology (2011) 0.95
Epigenetic silencing of beta-spectrin, a TGF-beta signaling/scaffolding protein in a human cancer stem cell disorder: Beckwith-Wiedemann syndrome. J Biol Chem (2010) 0.95
Radiation protection by a new chemical entity, Ex-Rad: efficacy and mechanisms. Radiat Res (2009) 0.92
A role for the epidermal growth factor receptor signaling in development of intestinal serrated polyps in mice and humans. Gastroenterology (2012) 0.92
Enantiomers of an indole alkaloid containing unusual dihydrothiopyran and 1,2,4-thiadiazole rings from the root of Isatis indigotica. Org Lett (2012) 0.92
Diversity of organophosphorus pesticide-degrading bacteria in a polluted soil and conservation of their organophosphorus hydrolase genes. Can J Microbiol (2005) 0.92
Studies on psychopharmacological effects of Cleome viscosa Linn. extract in rats and mice. Phytother Res (2004) 0.91
Myb permits multilineage airway epithelial cell differentiation. Stem Cells (2014) 0.90
The incorporation of APOBEC3 proteins into murine leukemia viruses. Virology (2008) 0.90
JNK-interacting leucine zipper protein is a novel scaffolding protein in the Galpha13 signaling pathway. Biochemistry (2005) 0.88
Design, synthesis, and biological evaluation of 1-(4-sulfamylphenyl)-3-trifluoromethyl-5-indolyl pyrazolines as cyclooxygenase-2 (COX-2) and lipoxygenase (LOX) inhibitors. Bioorg Med Chem (2008) 0.87
Dehalogenation of chlorobenzenes, dichlorotoluenes, and tetrachloroethene by three Dehalobacter spp. Environ Sci Technol (2014) 0.87
Cloning of the organophosphorus pesticide hydrolase gene clusters of seven degradative bacteria isolated from a methyl parathion contaminated site and evidence of their horizontal gene transfer. Biodegradation (2006) 0.87
A connected set of genes associated with programmed cell death implicated in controlling the hypersensitive response in maize. Genetics (2012) 0.87
Regulation of neurite outgrowth by interactions between the scaffolding protein, JNK-associated leucine zipper protein, and neuronal growth-associated protein superior cervical ganglia clone 10. J Biol Chem (2009) 0.87
Molecular characterization of the enzymes involved in the degradation of a brominated aromatic herbicide. Mol Microbiol (2013) 0.87
Evaluation of antipyretic potential of Clitoria ternatea L. extract in rats. Phytomedicine (2004) 0.86
Transforming pathways activated by the v-Abl tyrosine kinase. Oncogene (2002) 0.86
Hydrolytic dechlorination of chlorothalonil by Ochrobactrum sp. CTN-11 isolated from a chlorothalonil-contaminated soil. Curr Microbiol (2010) 0.86
Inhibition of tumor angiogenesis in vivo by a monoclonal antibody targeted to domain 5 of high molecular weight kininogen. Blood (2004) 0.85
A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition. Genes Cancer (2010) 0.85
Evaluation of anti-diarrheal activity of Cleome viscosa L. extract in rats. Phytomedicine (2002) 0.85
Novel coumarin-3-(N-aryl)carboxamides arrest breast cancer cell growth by inhibiting ErbB-2 and ERK1. Bioorg Med Chem (2005) 0.85
Endodermal differentiation of murine embryonic carcinoma cells by retinoic acid requires JLP, a JNK-scaffolding protein. J Cell Biochem (2006) 0.84
Neoplastic transformation induced by the gep oncogenes involves the scaffold protein JNK-interacting leucine zipper protein. Neoplasia (2011) 0.84
B-myb is an essential regulator of hematopoietic stem cell and myeloid progenitor cell development. Proc Natl Acad Sci U S A (2014) 0.83
Synthesis of new coumarin 3-(N-aryl) sulfonamides and their anticancer activity. Bioorg Med Chem Lett (2004) 0.83
Degradation of methamidophos by Hyphomicrobium species MAP-1 and the biochemical degradation pathway. Biodegradation (2009) 0.82
Integrated pharmacokinetic-driven approach to screen candidate anticancer drugs for brain tumor chemotherapy. AAPS J (2012) 0.82
Evaluation of antitussive activity of Lagerstroemia parviflora leaf extract. Phytother Res (2004) 0.82
Targeted inhibition of kinases in cancer therapy. Mt Sinai J Med (2010) 0.82
Mechanisms associated with IL-6-induced up-regulation of Jak3 and its role in monocytic differentiation. Blood (2004) 0.81
DH334, a beta-carboline anti-cancer drug, inhibits the CDK activity of budding yeast. Cancer Biol Ther (2007) 0.81
The unique structure of carbonic anhydrase αCA1 from Chlamydomonas reinhardtii. Acta Crystallogr D Biol Crystallogr (2011) 0.81
Facilitation of bacterial adaptation to chlorothalonil-contaminated sites by horizontal transfer of the chlorothalonil hydrolytic dehalogenase gene. Appl Environ Microbiol (2011) 0.81
Requirement of Cdk4 for v-Ha-ras-Induced Breast Tumorigenesis and Activation of the v-ras-Induced Senescence Program by the R24C Mutation. Genes Cancer (2010) 0.81
A novel hydrolytic dehalogenase for the chlorinated aromatic compound chlorothalonil. J Bacteriol (2010) 0.81
Impaired adult myeloid progenitor CMP and GMP cell function in conditional c-myb-knockout mice. Cell Cycle (2012) 0.81
Co-metabolism of DDT by the newly isolated bacterium, Pseudoxanthomonas sp. wax. Braz J Microbiol (2010) 0.80
c-Myc is essential but not sufficient for c-Myb-mediated block of granulocytic differentiation. J Biol Chem (2003) 0.80
Horizontal transfer of dehalogenase genes involved in the catalysis of chlorinated compounds: evidence and ecological role. Crit Rev Microbiol (2011) 0.80
Preclinical pharmacological evaluation of a novel multiple kinase inhibitor, ON123300, in brain tumor models. Mol Cancer Ther (2014) 0.80
Mechanism of failure eleven years following a Buechel Pappas hip resurfacing. Acta Orthop Belg (2007) 0.80
Preclinical pharmacokinetic and pharmacodynamic evaluation of novel anticancer agents, ON01910.Na (Rigosertib, Estybon™) and ON013105, for brain tumor chemotherapy. Pharm Res (2012) 0.79
p21 loss cooperates with INK4 inactivation facilitating immortalization and Bcl-2-mediated anchorage-independent growth of oncogene-transduced primary mouse fibroblasts. Cancer Res (2007) 0.79